Viral and nonviral gene delivery vectors for cancer gene therapy.
The development of vectors that are capable of efficient gene delivery is crucial to the success of gene therapy. We have developed both recombinant viral and nonviral vectors with the goal of correcting genetic abnormalities in cancer cells that are responsible for malignant transformation. Infection of cancer cells by recombinant adenovirus (Adv) indicates that the level of transduction is variable and dependent on the virus-to-cell ratio. Infection of cells with Adv/p53 resulted in levels of tumor suppressor p53 gene expression that could mediate tumor cell growth suppression and apoptosis, both in vitro and in vivo. The treatment of cancer cells with cisplatin prior to Adv transduction resulted in a higher level of therapeutic gene expression. Epidermal growth factor (EGF)/DNA complexes targeted to cancer cells overexpressing the EGF receptor resulted in efficient transduction of several lung cancer cell lines in vitro. As a result, these vectors provide improved methods with which to treat cancer in the clinical setting with gene therapy.
Cristiano
R J
RJ
Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Xu
B
B
Nguyen
D
D
Schumacher
G
G
Kataoka
M
M
Spitz
F R
FR
Roth
J A
JA
D000256:Adenoviridae / Q000235:genetics; D000704:Analysis of Variance; D000818:Animals; D002460:Cell Line; D004815:Epidermal Growth Factor / Q000235:genetics; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009369:Neoplasms / Q000628:therapy*; D012190:Retroviridae / Q000235:genetics; D014407:Tumor Cells, Cultured
D004815:Epidermal Growth Factor